Additionally, Funakoshi et al. [13] have described an increased risk of high grade infection (HR, 1.21) and febrile neutropenia (HR, 1.28) in a meta-analysis of 10,094 patients in 13 randomized controlled trials of the HER2-directed antibodies trastuzumab and/or pertuzumab [13]. This evidence concerns the gene ERBB2 and infection.